Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients

Blood

Volumn 121, Issue 12, 2013, Pages 2347-2351

  Li, Jian Ming ^a   Hossain, Mohammad S ^a   Southerland, Lauren ^b   Waller, Edmund K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; (VIP NEUROTENSIN) HYBRID ANTAGONIST; (VIP-NEUROTENSIN) HYBRID ANTAGONIST; HYBRID PROTEIN; NEUROTENSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MURINE CYTOMEGALOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TH1 CELL; VIRUS LOAD; WILD TYPE; ADAPTIVE IMMUNITY; ALLOTRANSPLANTATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; EVALUATION; GENETICS; HERPES VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MORTALITY; MOUSE MUTANT; MUROMEGALOVIRUS; SURVIVAL; UPREGULATION;

ADAPTIVE IMMUNITY; ANIMALS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; GRAFT VS HOST DISEASE; HERPESVIRIDAE INFECTIONS; IMMUNOCOMPROMISED HOST; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUROMEGALOVIRUS; NEUROTENSIN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; UP-REGULATION; VASOACTIVE INTESTINAL PEPTIDE; VIRAL LOAD;

MLCS; MLOWN;

EID: 84877930633     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-437640     Document Type: Article

References (25)

1. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, et al. Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood. 2006;107(9):3787-3794.
2. Delgado M, Gonzalez-Rey E, Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol. 2005;175(11):7311-7324.
3. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, et al. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood. 2006;107(9):3632-3638.
4. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004;56(2):249-290.
5. Gomariz RP, Delgado M, Naranjo JR, et al. VIP gene expression in rat thymus and spleen. Brain Behav Immun. 1993;7(4):271-278.
6. Lygren I, Revhaug A, Burhol PG, et al. Vasoactive intestinal polypeptide and somatostatin in leucocytes. Scand J Clin Lab Invest. 1984;44(4):347-351.
7. Leceta J, Martinez MC, Delgado M, et al. Lymphoid cell subpopulations containing vasoactive intestinal peptide in the rat. Peptides. 1994;15(5):791-797.
8. Li JM, Southerland L, Hossain MS, et al. Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice. J Immunol. 2011; 187(2):1057-1065.
9. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9(9):543-558.
10. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95(7):2240-2245.
11. Gozes I, Fridkin M, Brenneman DE. A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Cell Mol Neurobiol. 1995; 15(6):675-687.
12. Waller EK, Ship AM, Mittelstaedt S, et al. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. Blood. 1999;94(9):3222-3233.
13. Li JM, Southerland LT, Lu Y, et al. Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation. J Immunol. 2009;183(12): 7799-7809.
14. Hossain MS, Roback JD, Pollack BP, et al. Chronic GvHD decreases antiviral immune responses in allogeneic BMT. Blood. 2007; 109(10):4548-4556.
15. Hossain MS, Roback JD, Wang F, et al. Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. J Immunol. 2008;180(10):6892-6902.
16. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.
17. Bopp T, Becker C, Klein M, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med. 2007; 204(6):1303-1310.
18. Delgado M. Generating tolerogenic dendritic cells with neuropeptides. Hum Immunol. 2009;70(5):300-307.
19. Redpath S, Angulo A, Gascoigne NR, et al. Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J Immunol. 1999;162(11):6701-6707.
20. Brown KE, Freeman GJ, Wherry EJ, et al. Role of PD-1 in regulating acute infections. Curr Opin Immunol. 2010;22(3):397-401.
21. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239-245.
22. Crawford A, Wherry EJ. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr Opin Immunol. 2009;21(2):179-186.
23. Li JM, Giver CR, Lu Y, et al. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy. 2009;1(4):599-621.
24. Li JM, Waller EK. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2004;10(8):540-551.
25. Lu Y, Giver CR, Sharma A, et al. IFN-g and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood. 2012;119(4):1075-1085.